MolMed Acute Leukaemias: Contribution of TK presented at the BMT Tandem Meetings

MolMed S.p.A. announces the results of the contribution given by its investigational cell-based therapy TK to the treatment of haematologic malignancies through bone marrow transplantation from partially matched donors, presented at the Blood & Marrow Transplantation Tandem Meetings, the combined annual meeting of the Center for International Blood ... (more)

http://ireport.cnn.com/docs/DOC-929661?ref=feeds%2Flatest